BC
PHAT icon

Bridgefront Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Bridgefront Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,954
Closed -$166K – 692
2026
Q1 		$166K Sell
14,954
-2,027
-12% -$25.6K 0.04% 481
2025
Q4 		$282K Buy
+16,981
New +$243K 0.07% 386

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bridgefront Capital's PHAT Position: Q2 2026 in Review

Bridgefront Capital sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 14,954 shares — an estimated $166K sold.

Bridgefront Capital first reported a position in PHAT in Q4 2025 and held it in 2 quarters. The position peaked at $282K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Bridgefront Capital reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 14,954 Phathom Pharmaceuticals shares in Q2 2026, an estimated $166K.
  • Bridgefront Capital first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Bridgefront Capital's Phathom Pharmaceuticals position peaked at $282K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.